| Date Filed | Type | Description |
| 08/14/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
SC 13D
| Monograph Capital Holdings Advisors, LLC reports a 5.4% stake in UROGEN PHARMA LTD. |
| 08/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/27/2023 |
4
| Robinson James A. Jr. (Director) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Granted 20,000 options to buy
@ $8.9, valued at
$178k
|
|
| 07/27/2023 |
3
| Robinson James A. Jr. (Director) has filed a Form 3 on UroGen Pharma Ltd. |
| 07/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of July 2023 Pre-Funded Warrant",
"Securities Purchase Agreement, by and among UroGen Pharma Ltd. and the Purchasers named therein",
"UroGen Announces $120 Million Private Placement of Ordinary Shares PRINCETON, N.J.—July 27, 2023— UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to selected institutional and accredited investors. RA Capital Management L.P. and Great Point Partners LLC led the Private Placement, which also included Acorn Bioventures, Monograph Capital and Horton Capital Partners Fund, LP. UroGen expects to receive gross proceeds of approximately $120 million, before deducting placement agent commissions and other offering expenses. UroGen intends to use the net proceeds of the Private ...",
"Company Presentation",
"Trial Results Slides" |
|
| 07/25/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
SC 13G/A
| MENORA MIVTACHIM HOLDINGS LTD. reports a 12.4% stake in UroGen Pharma Ltd. |
| 06/09/2023 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Granted 30,000 restricted stock units
@ $0 |
|
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
4/A
| Nussbaum Ran (Director) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Exercised 1,030 options to buy
@ $5, valued at
$5.2k
|
|
| 02/28/2023 |
4/A
| Nussbaum Ran (Director) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Exercised 32,723 options to buy
@ $5.94, valued at
$194.4k
Exercised 15,276 options to buy
@ $5.94, valued at
$90.7k
|
|
| 02/28/2023 |
4
| Nussbaum Ran (Director) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Exercised 2,211 options to buy
@ $5, valued at
$11.1k
|
|
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
4
| Barrett Elizabeth A. (CEO) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Exercised 5,000 restricted stock units
@ $0
Exercised 13,333 restricted stock units
@ $0
Granted 75,000 restricted stock units
@ $0
Granted 125,000 options to buy
@ $10.39, valued at
$1.3M
Granted 100,000 rights
@ $0 |
|
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Smith Jason Drew (General Counsel) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Sold 409 shares
@ $10.12, valued at
$4.1k
Sold 1,227 shares
@ $10.12, valued at
$12.4k
Exercised 833 restricted stock units
@ $0
Exercised 2,500 restricted stock units
@ $0
Granted 20,000 restricted stock units
@ $0
Granted 40,000 options to buy
@ $10.39, valued at
$415.6k
|
|
| 02/02/2023 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Sold 248 shares
@ $10.12, valued at
$2.5k
Sold 991 shares
@ $10.12, valued at
$10k
Sold 661 shares
@ $10.12, valued at
$6.7k
Exercised 500 restricted stock units
@ $0
Exercised 2,000 restricted stock units
@ $0
Exercised 1,333 restricted stock units
@ $0
Granted 10,000 restricted stock units
@ $0
Granted 30,000 options to buy
@ $10.39, valued at
$311.7k
|
|
| 01/23/2023 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.|
Txns:
| Exercised 122,677 options to buy
@ $5, valued at
$613.4k
|
|
| 12/02/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/01/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/30/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/16/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 11/15/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|